RT Journal Article
T1 CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.
A1 Moscoso, Alexis
A1 Karikari, Thomas K
A1 Grothe, Michel J
A1 Ashton, Nicholas J
A1 Lantero-Rodriguez, Juan
A1 Snellman, Anniina
A1 Zetterberg, Henrik
A1 Blennow, Kaj
A1 Schöll, Michael
AB Clinical trials targeting tau in Alzheimer's disease (AD) need to recruit individuals at risk of tau accumulation. Here, we studied cerebrospinal fluid (CSF) biomarkers and plasma phosphorylated tau (p-tau)181 as predictors of tau accumulation on positron emission tomography (PET) to evaluate implications for trial designs. We included older individuals who had serial tau-PET scans, baseline amyloid beta (Aβ)-PET, and baseline CSF biomarkers (n = 163) or plasma p-tau181 (n = 74). We studied fluid biomarker associations with tau accumulation and estimated trial sample sizes and screening failure reductions by implementing these markers into participant selection for trials. P-tau181 in CSF and plasma predicted tau accumulation (r > 0.36, P  0.36, P  0.37, P  Clinical trials testing tau-targeting therapies may benefit from using fluid biomarkers to recruit individuals at risk of tau aggregation.
YR 2022
FD 2022-02-28
LK http://hdl.handle.net/10668/20174
UL http://hdl.handle.net/10668/20174
LA en
DS RISalud
RD Apr 19, 2025